Stock Split History
ETFs Holding VRTX »    VRTX Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Vertex Pharmaceuticals is engaged in developing and commercializing therapies for the treatment of cystic fibrosis (CF). Co.'s marketed medicines are SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is developing VX-150, a NaV1.8 inhibitor, as a potential treatment for pain. Co. is co-developing CTX001, an investigational gene editing treatment, for the treatment of beta-thalassemia and sickle cell disease, with CRISPR Therapeutics AG. According to our Vertex Pharmaceuticals stock split history records, Vertex Pharmaceuticals has had 1 split.
Vertex Pharmaceuticals stock split history picture
Vertex Pharmaceuticals (VRTX) has 1 split in our Vertex Pharmaceuticals stock split history database. The split for VRTX took place on August 24, 2000. This was a 2 for 1 split, meaning for each share of VRTX owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as Vertex Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the Vertex Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vertex Pharmaceuticals shares, starting with a $10,000 purchase of VRTX, presented on a split-history-adjusted basis factoring in the complete Vertex Pharmaceuticals stock split history. Vertex Pharmaceuticals split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/19/2009
End date: 06/18/2019
Start price/share: $33.36
End price/share: $177.94
Dividends collected/share: $0.00
Total return: 433.39%
Average Annual Total Return: 18.22%
Starting investment: $10,000.00
Ending investment: $53,346.84
Years: 10.00
Date Ratio
08/24/20002 for 1
VRTX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

VSCP Split History
VVUS Split History
WAT Split History
WGBS Split History
WOOF Split History
XOMA Split History
XRAY Split History
XTNT Split History
ZGNX Split History
ZLCS Split History

Also explore: VRTX shares outstanding history

Hudson Global, Inc. (HSON)
Jaguar Health, Inc. (JAGX)
Cesca Therapeutics Inc. (KOOL)
Northern Technologies International Corporation (NTIC)
Digirad Corporation (DRAD)
Hemispherx Biopharma, Inc. (HEB)
ContraVir Pharmaceuticals, Inc. (CTRV)
Seadrill Partners LLC (SDLP)
Direxion Daily Semiconductor Bear 3X Shares (SOXS)
Direxion Daily Daily MSCI Real Estate Bear 3X Shares (DRV)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Vertex Pharmaceuticals
Vertex Pharmaceuticals Insider Buying

Vertex Pharmaceuticals Stock Split History | www.StockSplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.StockSplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.